Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Apatinib in AFP-elevated Gastric Adenocarcinoma
NCT04006821Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and Rivoceranib in gastric adenocarcinoma, sponsored by China Medical University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04006821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006821.